MRTX News and Press, Mirati Therapeutics Inc. From 05/26/22

Gainers: Adicet  (ACET) +25%. PMV Pharmaceuticals (PMVP) +20%. Red Robin Gourmet Burgers (RRGB) +18%. Aesthetic Medical International Holdings Group  (AIH) +13%. Elevation Oncology (ELEV) +9%. Losers: Iovance Biotherapeutics (IOVA) -50%. Aurora Cannabis  (ACB) -18%. M...

Investigational Adagrasib Delivers Positive Results in Registration-Enabling Study of Patients with KRASG12C-Mutated Advanced Non-Small Cell Lung Cancer PR Newswire SAN DIEGO , May 26, 2022 /PRNewswire/ -- Mirati Therapeutics, Inc. (NASDAQ: MRTX), a c...

Baron is an asset management firm focused on delivering growth equity investment solutions known for a long-term, fundamental, active approach to growth investing. In the quarter ended March 31, 2022, Baron Health Care Fund (the “Fund”) declined 9.93% (Institutional Shar...

Guggenheim Analyst Michael Schmidt upgraded Mirati Therapeutics (NASDAQ:MRTX) ratings to Buy from Neutral with a $115 price target. Shares were trading +5.64% at $62.97. The new comes after MRTX submitted a marketing application to the European Union's drug regul...

Mirati Therapeutics (NASDAQ:MRTX) on Thursday said it had submitted a marketing application to the European Union's drug regulator for its investigational inhibitor adagrasib for the treatment of patients with non-small cell lung cancer (NSCLC) with a certain mutation who have got a least one...

Mirati Therapeutics Submits Marketing Authorization Application to the European Medicines Agency for Investigational Adagrasib as a Treatment for Previously-Treated KRASG12C-mutated Non-Small Cell Lung Cancer PR Newswire Submission follows the U.S. FDA acceptance of th...

Mirati Therapeutics (NASDAQ:MRTX) said Monday it appointed Laurie Stelzer as CFO, effective May 16. Stelzer joins MRTX from Arena Pharmaceuticals, where she served as EVP and CFO since 2020. Vickie Reed, MRTX's chief accounting officer, filled the role of principal accounting office...

Mirati Therapeutics Appoints Laurie Stelzer as Chief Financial Officer PR Newswire SAN DIEGO , May 16, 2022 /PRNewswire/ -- Mirati Therapeutics, Inc. (NASDAQ: MRTX), a clinical-stage targeted oncology company, today announced the appointment of Laurie...

The following slide deck was published by Mirati Therapeutics, Inc. in conjunction with their 2022 Q1 earnings call. For further details see: Mirati Therapeutics, Inc. 2022 Q1 - Results - Earnings Call Presentation

Mirati Therapeutics, Inc. (MRTX) Q1 2022 Earnings Conference Call May 04, 2022, 04:30 PM ET Company Participants Ryan Asay - Vice President of Corporate Affairs David Meek - CEO James Christensen - Chief Scientific Officer Ben Hickey - Chief Commercial Officer Vickie Reed - CAO Daniel Faga - ...